摘要

OBJECTIVE:Several large clinical trials suggest that ACE inhibitors may reduce the incidence of diabetes. Less is known about the effects of angiotensin receptor blockers (ARBs) on reducing incident diabetes or leading to regression of impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) to normoglycemia.
RESEARCH DESIGN AND METHODS:Participants were 3,488 adults at high risk for cardiovascular disease but free from diabetes (mean age 67 years; 61% male) in the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) study. The participants were randomized to the ARB telmisartan 80 mg (n = 1,726) or placebo (n = 1,762) in addition to usual care.
RESULTS:During a median 56 months, 21.8% of participants treated with telmisartan and 22.4% of those on placebo developed diabetes (relative ratio 0.95 [95% CI 0.83-1.10]; P = 0.51). Participants originally diagnosed with IFG and/or IGT were equally likely to regress to normoglycemia (26.9 vs. 24.5%) or to progress to incident diabetes (20.1 vs. 21.1%; P = 0.59) on telmisartan or placebo.
CONCLUSIONS:There was no evidence that addition of the ARB telmisartan to usual care prevents incident diabetes or leads to regression of IFG or IGT in people at high risk for cardiovascular disease but free from diabetes.

译文

目的: 几项大型临床试验表明 ACE 抑制剂可能会降低糖尿病的发病率。关于血管紧张素受体阻滞剂 (ARBs) 在减少糖尿病事件或导致空腹血糖受损 (IFG) 或葡萄糖耐受受损 (IGT) 回归正常血糖方面的作用,人们知之甚少。
研究设计和方法: 参与者是 3,488 名心血管疾病高危成年人,但没有糖尿病 (平均年龄 67 岁; 61% 名男性) 在针对 ACE 不耐受的心血管疾病受试者的替米沙坦随机评估研究 (TRANSCEND) 研究中。参与者被随机分配给 ARB 替米沙坦 80 毫克 (n = 1,726) 或安慰剂 (n = 1,762),除了常规护理。
结果: 在平均 56 个月的时间里,21.8% 接受替米沙坦治疗的参与者和 22.4% 接受安慰剂治疗的参与者发展成糖尿病 (相对比率 0.95 [95% CI 0.83-1.10]; P = 0.51)。最初被诊断为 IFG 和/或 IGT 的参与者同样可能回归正常血糖 (26.9 对 24.5%) 或进展为糖尿病 (20.1 对 21.1%; P = 0.59) 替米沙坦或安慰剂。
结论: 没有证据表明在常规护理中添加 ARB 替米沙坦可以预防糖尿病事件或导致心血管疾病高危人群的 IFG 或 IGT 消退,但没有糖尿病。

Telmisartan

心血管 原发性高血压 药物
概述  :  

适应证适于原发性高血压的治疗。用法用量1.应个体化口服给药,常用初始剂量为每口1次,每次40 mg。2.在20-80 mg的剂量范围内,替米沙坦的降压疗效与剂量有关,即如果未达到理想血压可加大剂量,最大剂量为每日1次80 mg。因为替米沙坦在疗程开始后4-8周才能发挥最大药效,所以调整剂量时应注意在此时间之后再进行。主要不良反应1.该药不良反应很少,即使有也很轻微,一般不需停药。2.安慰剂对照的临床试验表明替米沙坦的不良反应与安慰剂无明显差别。不良反应与患者性别、年龄和种族无关。试验观察到的不良

Telmisartan

释义   替米沙坦

例句   Telmisartan is a new kind of pharmaceutical for hypertension. 

替米沙坦是一种抗高血压新药。


请扫描右侧二维码,免费查看词汇专业知识背景